PEG-uricase Recruiting Phase 4 Trials for Tumour lysis syndrome / Malignant Solid Neoplasms / Hematopoietic and Lymphoid System Neoplasm Treatment

Indications	Status	Purpose	Phase
DBCOND0015846 (Tumour lysis syndrome) DBCOND0067750 (Malignant Solid Neoplasms) DBCOND0132171 (Hematopoietic and Lymphoid System Neoplasm)	Recruiting	Treatment	4

clinicaltrials.gov Identifier	Title	Drugs
NCT04745910	Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome	PEG-uricase (DB05321) Pegloticase (DB09208) Rasburicase (DB00049) Uric acid (DB08844)